Skip to content
by Legal Desire
9 July 2021

Kirkland Advises on $400 Million Hong Kong IPO of Keymed Biosciences

Advising firms

Deal team

1 lawyer named
LawyerFirmSeniorityPracticeOffice
Mengyu Lu Lead Kirkland & Ellis Partner capital markets Not stated

Stated terms

Stated value
USD 400m ($400 million)
What the figure measures
Issue size
Client
Not stated
Counterparties
Morgan Stanley (Underwriters)
China International Capital Corporation (Underwriters)
Huatai Financial (Underwriters)
China Everbright Securities (Underwriters)